Equity Profile

TWST

Twist Bioscience Corporation

Health CareBiotechnology$7.9B

Aug3Mon

Pre-Earnings Brief

UpcomingQ3-2026Pre-Market9:00 AM EDT

Company Snapshot

Twist Bioscience Corporation operates in the biotechnology sector, focusing on synthetic DNA production. Their technology is crucial for various applications, including pharmaceuticals and genetic research, making them a key player in the health care industry.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if the company can narrow its losses.

$-0.18

Revenue

Revenue growth indicates demand for Twist's products and services, which is essential for the company's financial health.

$115M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2 2026, Twist reported an EPS of $-0.71, missing estimates and resulting in a stock decline of nearly 7% the following day. The company continues to face challenges in achieving profitability.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a slight improvement in EPS and revenue this quarter, but there is uncertainty given the company's recent performance. The market is watching closely for any signs of recovery.

Bull Case

If Twist can meet or exceed the consensus estimates, it may signal a turnaround in their financial performance, boosting investor confidence.

Bear Case

Conversely, another earnings miss could deepen concerns about the company's ability to manage costs and generate revenue, leading to further stock declines.

Key Metrics to Watch

EPS

$-0.18

Earnings per share is a critical measure of profitability, and investors will be keen to see if the company can narrow its losses.

Revenue

$115M

Revenue growth indicates demand for Twist's products and services, which is essential for the company's financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Twist Bioscience achieve revenue of at least $115M this quarter?

Meeting this revenue target is crucial for demonstrating demand and operational efficiency, which investors are closely monitoring.

Can the company narrow its EPS loss to $-0.18 or better?

A smaller loss would indicate progress towards profitability and could positively influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Twist to achieve revenue growth driven by new product demand, despite recent misses.

Supporting Evidence

The options market is pricing a 39.3% move, indicating expectations of significant volatility regardless of the outcome.

Twist's historical performance shows that even with misses, there have been instances of recovery in stock price following earnings.

Key Risk

If revenue exceeds $115M, it could challenge the bearish outlook and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for assessing the company's recovery trajectory and operational effectiveness.

Bull Confirmed If

Achieving revenue of $115M or more with an EPS loss of $-0.18 or better would confirm a positive outlook.

Bear Confirmed If

An EPS loss greater than $-0.20 and revenue below $114M would reinforce negative sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±39.3%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations, history suggests a potential stock increase of around 0.91%, confirming a positive shift in momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 6.11%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiencies.
3Insights into customer demand trends and how they align with revenue expectations.
4Any guidance on future quarters and how the company plans to achieve profitability.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if the company can narrow its losses.

$-0.18

Revenue

Revenue growth indicates demand for Twist's products and services, which is essential for the company's financial health.

$115M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2 2026, Twist reported an EPS of $-0.71, missing estimates and resulting in a stock decline of nearly 7% the following day. The company continues to face challenges in achieving profitability.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a slight improvement in EPS and revenue this quarter, but there is uncertainty given the company's recent performance. The market is watching closely for any signs of recovery.

Bull Case

If Twist can meet or exceed the consensus estimates, it may signal a turnaround in their financial performance, boosting investor confidence.

Bear Case

Conversely, another earnings miss could deepen concerns about the company's ability to manage costs and generate revenue, leading to further stock declines.

Key Metrics to Watch

EPS

$-0.18

Earnings per share is a critical measure of profitability, and investors will be keen to see if the company can narrow its losses.

Revenue

$115M

Revenue growth indicates demand for Twist's products and services, which is essential for the company's financial health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Twist Bioscience achieve revenue of at least $115M this quarter?

Meeting this revenue target is crucial for demonstrating demand and operational efficiency, which investors are closely monitoring.

Can the company narrow its EPS loss to $-0.18 or better?

A smaller loss would indicate progress towards profitability and could positively influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Twist to achieve revenue growth driven by new product demand, despite recent misses.

Supporting Evidence

The options market is pricing a 39.3% move, indicating expectations of significant volatility regardless of the outcome.

Twist's historical performance shows that even with misses, there have been instances of recovery in stock price following earnings.

Key Risk

If revenue exceeds $115M, it could challenge the bearish outlook and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for assessing the company's recovery trajectory and operational effectiveness.

Bull Confirmed If

Achieving revenue of $115M or more with an EPS loss of $-0.18 or better would confirm a positive outlook.

Bear Confirmed If

An EPS loss greater than $-0.20 and revenue below $114M would reinforce negative sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±39.3%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations, history suggests a potential stock increase of around 0.91%, confirming a positive shift in momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 6.11%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiencies.
3Insights into customer demand trends and how they align with revenue expectations.
4Any guidance on future quarters and how the company plans to achieve profitability.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.